Efficacy differences of MHSP65-TCL vaccine in the treatment of triple-negative breast cancer of different pathological types
Objective To evaluate and compare the efficacy and differences of the MHSP65-TCL(modi-fied mycobacterium tuberculosis heat-shock protein 65 tumor cell lysate)vaccine for different types of triple-negative breast cancer.Methods Firstly,bioinformatics was used to analyse immune cell infiltration and ac-tivation in the tumor microenvironment of different pathological types of triple-negative breast cancer.Second-ly,this study analyzed the abundance of cell-activating factors such as RACK1,Bcl-2,CTNNBL1,and apopto-sis-inducing factors PDL1,HMGB1,Fas-L in triple-negative breast cancer cells and their signaling pathways affecting immune cell activation.Then,we prepared MHSP65-TCL to remove PDL1 from TCL or to increase Bcl-2 in TCL,and then tested and compared the effects of these two methods in treating different types of tri-ple-negative breast cancer through in vivo and in vitro anti-tumor assays.Results The expression of HMGB1 was the highest in MDA-MB-453 cells,but the expression of Bcl-2 was the lowest.Combined with lymphatic invasion of various types of triple-negative breast cancer,in vitro killing assays and in vivo animal experiments,three different types of triple-negative breast cancer cells,(especially the LAR cell line MDA-MB-453)mainly relied on HMGB1 to suppress immune cells.Removal of HMGB1 from TCL could improve the anti-tumor effect of MHSP65-TCL more effectively.Conclusion This study elucidates the difference in efficacy and mechanism of MHSP65-TCL vaccine on each type of triple-negative breast cancer,and establishes a new meth-od for the treatment of triple-negative breast cancer.
triple-negative breast cancerbioinformaticstumor cell lysateimmune cell infiltrationan-ti-tumor vaccine
万方数据
维普
